Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G SWAIN

Showing results (171-180 of 197) with videos related to

Pageof 20
Sort By:
NPJ Vaccines|January 12, 2021
Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)Shivali S Joshi, Rachelle P Davis, Mang M Ma, et al.
Gastrointestinal Endoscopy|November 5, 2016
Clinical prediction rule to determine the need for repeat ERCP after endoscopic treatment of postsurgical bile leaksApostolos V Tsolakis, Paul D James, Gilaad G Kaplan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2008
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Paul Marotta, et al.
The Journal of Investigative Dermatology|February 27, 2017
Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based StudyRyan T Lewinson, Isabelle A Vallerand, Mark W Lowerison, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 29, 2021
Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, CanadaAbdel Aziz Shaheen, Kristine Kong, Christopher Ma, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Frontiers in Immunology|April 20, 2019
The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center StudyGary L Norman, Anna Reig, Odette Viñas, et al.
Brain, Behavior, and Immunity|March 8, 2022
Colitis-associated microbiota drives changes in behaviour in male mice in the absence of inflammationFernando A Vicentini, Jake C Szamosi, Laura Rossi, et al.
CMAJ Open|January 7, 2018
Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patientsAlex I Aspinall, Abdel A Shaheen, Golasa S Kochaksaraei, et al.
Pageof 20

Showing results (171-180 of 197) with videos related to

Sort By:
Pageof 20
NPJ Vaccines|January 12, 2021
Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)Shivali S Joshi, Rachelle P Davis, Mang M Ma, et al.
Gastrointestinal Endoscopy|November 5, 2016
Clinical prediction rule to determine the need for repeat ERCP after endoscopic treatment of postsurgical bile leaksApostolos V Tsolakis, Paul D James, Gilaad G Kaplan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2008
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Paul Marotta, et al.
The Journal of Investigative Dermatology|February 27, 2017
Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based StudyRyan T Lewinson, Isabelle A Vallerand, Mark W Lowerison, et al.
Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 29, 2021
Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, CanadaAbdel Aziz Shaheen, Kristine Kong, Christopher Ma, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Frontiers in Immunology|April 20, 2019
The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center StudyGary L Norman, Anna Reig, Odette Viñas, et al.
Brain, Behavior, and Immunity|March 8, 2022
Colitis-associated microbiota drives changes in behaviour in male mice in the absence of inflammationFernando A Vicentini, Jake C Szamosi, Laura Rossi, et al.
CMAJ Open|January 7, 2018
Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patientsAlex I Aspinall, Abdel A Shaheen, Golasa S Kochaksaraei, et al.
Pageof 20